Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Take a peek at Planet 13.
$MJNA Phyto Animal Health offers a line of cannabidiol (CBD) hemp oil supplements and hemp products targeted to cats, dogs and horses. CBD hemp oil has been researched by top veterinarians for cardiovascular, orthopedic and mental health in animals. https://investors.medicalmarijuanainc.com/medical-marijuana-inc-subsidiary-phyto-animal-health-names-ian-quinn-ceo/
$CLSH:CSE $LILY:CSE $LIHT: CSE
Nevada Marijuana Retail Store(s) Sets New Record for Monthly Revenue, Exceeding USD $1,000,00.00
LAS VEGAS, NV, April 2019 - The Oasis Cannabis dispensary in Las Vegas, Nevada, and the City Trees brand, both have set a new record for the most revenue in a single month, with total combined net revenue in Nevada exceeding USD $1 Million in March, 2019. See Under The Radar CBD Co’s Now! http://www.thestreetnow.com/spotlight/marijuana-stock-alerts/
$NIO another Sizzler!!!!
$BBT.C Benchmark Botanics is expected to announce its first revenues from its first two harvests.
#cannabis #stocks #marijuana #investing
https://benchmarkbotanics.com/wp-content/uploads/2018/05/FacilityTour.mp4?fs=1&rel=0&enablejsapi=1&version=3
$FTEG #CBD #HEMPOIL
News Alert – For The Earth Launches Inline Store – OTC: FTEG
News Alert – For The Earth Launches Inline Store – OTC: FTEG
For The Earth Corporation (OTC: FTEG) Signs Lease With Town Square Mall in Las Vegas, NV to Launch Inline Store Sales Center
PHOENIX, AZ, Feb. 12, 2019 (GLOBE NEWSWIRE) -- For The Earth Corporation (OTC: FTEG) is pleased to announce that they have signed a Lease with the Town Square Mall in Las Vegas, NV. Read More Now! http://www.thestreetnow.com/spotlight/dailynews/
CANN GLOBAL sounds better then previous name… it`s companion in California had strong news now;
https://www.barchart.com/stocks/quotes/LDS.CN/overview
https://investorshub.advfn.com/Queensland-Bauxit-Ltd-(MMJ-hemp)-New-name;-Cann-Global-Ltd-ASX-CGB-33084/
$FTEG
Multi-National Consumer Conglomerates - Ground Floor Opportunity
For The Earth Corporation (OTC: FTEG) – News Alert – an Institutional Cleaning, Pet, and the Health Care Industry company has signed a Letter of Intent to acquire their CBD Vending Machine Division (CHOW). The Stock is currently trading at $.001 and a 52 week high of $0.01. See More Now! http://www.thestreetnow.com/spotlight/dailynews/
$LIHTF $LIHT
Medical Marijuana - Hemp Oil / CBD
Liht Cannabis Corp. (CSE: LIHT | OTCQX: LIHTF | FSE: 2M0) - Closed Up 5% - News Alert - Completely Integrated Cannabis Company - 52 Week High $1.23 CAD and $0.90 USD – Optimal Entry Point Now! See More http://www.thestreetnow.com/spotlight/dailynews/
Liht Cannabis Corp (CSE: LIHT | OTCQX: LIHTF | FSE: 2M0) A medical and recreational diversified cannabis company including cultivation, production and dispensary locations in key US locations based in Canada. – 52 Week High $1.23 CAD and $0.90 USD – Optimal Entry Point Now
! www.thestreetnow.com/spotlight/marijuana-stock-alerts/
$CLSH [b]Investor Ideas Potcasts Cannabis News and Stocks on the Move: Interview with Director of CLS Holdings USA, Inc. (OTCQB: CLSH) at Podcaster Row, MJBizCon Listen Now.
POINT ROBERTS, Wash. and LAS VEGAS, Nov 15, 2018 - CLS Holdings USA, Inc. (OTCQB: CLSH) Director Andrew Glashow sits down with Investor Ideas to discuss their business model, strategy and how their management team separates them from the pack Listen Now. Investor ideas a global news source covering marijuana and hemp stocks and its cannabis news and stocks to watch plus insight from thought leaders and experts. Read More. And for complete information: CLS Holdings USA, Inc. – OTCQB: CLSHhttps://www.investorideas.com/Audio/Podcasts/2018/111418-Potcasts-OTCQB-CLSH.mp3
$BBT.C / $BBHKF BENCHMARK MJ BOTANICS GRANTED "LICENSE TO SELL" FROM HEALTH CANADA
https://benchmarkbotanics.com/2018/09/05/benchmark-botanics-granted-license-to-sell/
$CBIX CBD Medical Marijuana China Clinical trials and research:
CIIX will further study the efficacy of CBD oil for the treatment of epilepsy and Alzheimer?s disease. Besides, the Company will invest in CBD drug R&D enterprises with the goal of developing various CBD drugs that have positive efficacy in combating Epilepsy and Alzheimer?s disease. The application period for new drugs of this type in China is 2 to 4 years, which is much shorter compared to that of FDA. Our goal is to be the first company in China to use CBD oil to help mitigate the suffering of patients with Epilepsy and Alzheimer?s disease.
http://chineseinvestors.com/opportunities-in-cbd/
thanks for the info
$CIIX After entering into a wholesale agreement with a well-know CBD health brand in December 2016, CIIX formally launched the new website for its new subsidiary ChineseCBDoil.com. The website went live on January 31, 2017 which is the world?s first CBD health products online store in the Chinese Language. The website will provide a variety of nutritional supplements containing CBD, including soft gels, capsules and concentrates, for Chinese-speaking customers worldwide. In upcoming months, CIIX will open a retail store in the predominantly Chinese community of San Gabriel, California, also where the Company?s headquarters are located.
http://www.chinesecbdoil.com/english/
$CIIX Usages and benefits of CBD
According to a series of documentary reports, CBD has shown to be effective in treating epilepsy, Alzheimer?s disease, cirrhosis of the liver and to provide relief from hangover, anxiety and stress.
http://chineseinvestors.com/opportunities-in-cbd/
$HEMP Hemp, Inc. Commended Oregon Legislature for Approving Commercial Hemp Expansion Bill
https://finance.yahoo.com/news/hemp-inc-commends-oregon-legislature-162455075.html
$HEMP Hemp Farming Act of 2018 Will Legalize Hemp and Spur New Market Opportunities
https://globenewswire.com/news-release/2018/04/17/1479990/0/en/Hemp-Farming-Act-of-2018-Will-Legalize-Hemp-and-Spur-New-Market-Opportunities.html
Learn about Willie Nelson and Bob MArley's son's company
Patient now easy access to Medical Marijuana today.
https://medicalmarijuanaservices.com.au/
Further information on the other announcement, our most significant announcement to date. Explanation on the two acquisitions, for both MCL and Medcan. We know,own 100% of these two businesses and moving forwards !
https://www.queenslandbauxite.com/
California marijuana stock with low float:
$VAPE
Distribution = Online & In Store
http://www.hiveceramics.com/authorized-shops
Government move to develop a major industry !
http://medicalrepublic.com.au/15377-2/15377
Hostile takeover in OTC??
https://twitter.com/cobrahawk69/status/996194863614976000?s=21
First GMP-certified cannapill to market ? It`s possible - march month it will reach Australia, coming in from Canada. Then it have to be approved by the FDA-of-Australia.
Strategy; establish a strong "first mover advantage" in Australia, then aim for the gigantic Asian market next door.
Hot; turned down a take-over-bid last week.
Take a look at Mrs Feldman track-record; built up a fortune selling tiny mining business to Kinross, DeBeers (worlds largest diamond comp.) and others. Her brother (on the board) diamond-magnate.
Now; Revenue start coming from there hemp products brand. Australias largest with "monopoly" on certain hemp products; they have the only state-of-the-art machines and supply there competion with the product = control of the source, control of the market.
https://docs.wixstatic.com/ugd/1943b6_9a2f1cc...545fad.pdf
$ACG.V $ALGWF - Alliance Growers MJ Botany Centre to Supply 300,000 Plantlets per Month
#marijuana #mj #Marijuanastocks #marijuananews #cannabis #investinginmj
http://tsxpennystocks.ca/marijuana/news/562-alliance-growers-mj-botany-centre-to-supply-300-000-plantlets-per-month
$BBT.C Benchmark Botanicals
ACMPR grow license in place
$5M Production Facility
#marijuana #mj #Marijuanastocks #marijuananews #cannabis #CannabisMedicinal
https://www.benchmarkbotanics.com/
U.S. and HEMP products pale in comparison to whole plant.
$KOSK Most Recent CBD News!
Oct 17, 2017
OTC Disclosure & News Service
-
One Step Vending, Corp. Announces a New Division in the Company Focusing on Multi-Billion Dollar CDB Products Sales and Online Market
HARRISON, NY--(Marketwired - Oct 17, 2017) - One Step Vending, Corp. (OTC PINK: KOSK), a holdings company specializing in market disruptive acquisitions with an emphasis on the self-serve vending market, after the recent agreement with Hemp Inc. (OTC PINK: HEMP), for the placement of CBD products in Micro Markets network, announces the Company's decision to direct its focus on multi-billion dollar CBD products marketing and sales online as well.
As hemp and marijuana-derived CBD products constitute an emerging industry with rapid growth and a multi-billion dollar market, the Company decided to dedicate part of its resources to the creation of an e-shop for the marketing and sale of selected CBD products online. The Company is already in discussions with manufacturers of CBD consumer products and is also exploring the potential to develop its own line under its own brand as revealed in previous press releases. Along with the San Diego Micro Markets on-the-spot network, the e-shop will be the vehicle for the online sale of CBD products.
Currently, the One Step Vending team after extensive market research develops its marketing strategy and works with its consultants and associates that are pioneers in the hemp and marijuana industry in the US. Also, the team works on the brand identity and the e-shop design and development which will be revealed in future press releases upon completion.
The Company aims to seize this emerging industry momentum as the legislation in both the United States and the European States becomes more and more favorable for hemp and marijuana-derived retail products for mass-consumption.
"We are excited for the new developments in the Company as this recently added direction for online sales of cannabinoid consumer products will amplify the scope and scale of our operations and accelerate growth for the Company and its investors," said Chief Executive Officer of One Step Vending Corp. Daniel Garfinkel.
Follow us on social media:
https://twitter.com/OneStepVend
https://www.facebook.com/onestepvending/
About One Step Vending Corporation
One Step Vending Corp. is a holding company focused on the acquisition of market-changing and disruptive business models. The Company supports subsidiaries with key financial, sales, marketing, and operational changes designed to accelerate growth and shareholder value. The Company has prioritized the development of Micro-Markets which are displacing vending machines with a small convenience store in thousands of offices across the Country, this transition will change the $7 billion vending industry by igniting growth in revenues and delivering fresher high-value products to meet new consumer demand.
For more information, visit http://www.onestepvending.com
About Corporate Refreshment Services-Micro Markets, Inc.
CRS-Micro Markets, Inc., a provider of a wide range of food and beverage solutions, focuses on the use of self-checkout Micro Market technology in the area of San Diego, California.
For more information, visit http://www.sdmicromarkets.com
Safe Harbor Statement
This release may contain forward-looking statements, including, without limitation, statements containing the words "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will", "could", "stands to" and "continues", as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of One Step Vending Corp., or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. One Step Vending Corp. expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.
Company Contact:
One Step Vending Corp.
Vasiliki Anagnostou
Secretary
600 Mamaroneck Ave.
Harrison, NY 10528
Tel: (619) 419-1220
E-mail: info@onestepvending.com
Copyright © 2017 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
$PMCB PharmaCyte Biotech’s Cannabis Research Program Sees Significant Progress in University of Northern Colorado Presentations PMCB
LAGUNA HILLS, Calif., April 10, 2017 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its research partner, the University of Northern Colorado (UNC), has made significant progress with PharmaCyte’s Cannabis Research Program. Of note, a parental cell line identical to that being used in PharmaCyte’s Cell-in-a-Box® + ifosfamide pancreas cancer therapy is being utilized to develop a therapy for cancer using cannabinoids as the chemotherapy agent.
Last week, UNC presented two scientific papers at the 253rd American Chemical Society (ACS) National Meeting & Exposition in San Francisco, California, themed “Advanced Materials, Technologies, Systems & Processes.” In these presentations, UNC presented a summary of its work with PharmaCyte’s Cannabis Research Program.
Mark L. Rabe, MD, PharmaCyte’s Director of Cannabis Program Development, said of the research being done by UNC, “There are several necessary components for a Cell-in-Box®/cannabinoid therapy to work. First, ‘active’ cannabinoid molecules need to exert an anti-cancer effect. The anti-cancer effects of cannabinoids, notably THC, or tetrahydrocannabinol, and CBD, or cannabidiol, are already well-documented in the medical literature against a broad range of cancers. Our research has independently confirmed this for CBD, and we have completed important preliminary dose-effect studies. Second, we need a ‘prodrug’ form of the ‘active’ molecule or molecules. We have this. Lastly, we need an enzyme-producing cell line, suitable for encapsulation, that will convert the ‘prodrug’ into the ‘active drug.’ In this regard, work is ongoing along several fronts, and UNC’s presentations give us confidence that the work shows promise.”
On April 4, 2017, UNC presented its work in the following two papers. The first paper, titled “Development of a cannabinoid-based Cell-in-a-Box® therapeutic system targeted toward malignant tumors,” was presented by Dr. Richard M. Hyslop, Principal Investigator and Professor of Chemistry and Biochemistry at UNC. In his presentation, Dr. Hyslop described PharmaCyte’s Cannabis research at UNC that was designed to develop a targeted cannabinoid-based chemotherapy utilizing the Cell-in-a-Box® live-cell encapsulation technology. This aspect of the UNC research has concentrated on the feasibility of developing cells capable of producing an enzyme that can convert an inactive phytocannabinoid (a Cannabis component) prodrug into an active anti-cancer drug. Cell-in-a-Box®, which encapsulates cells in a bio-inert cellulose-based porous polymer, serves as the platform for the therapy. Encapsulated cells with this prodrug-activating property could be implanted immediately upstream from a tumor. Then, the prodrug could be activated by the encapsulated cells at the site of the tumor.
Dr. Hyslop also described how specific phytocannabinoid prodrugs, including THC (tetrahydrocannabinol) and CBD (cannabidiol), and various model compounds have been screened for the desired activity across a variety of cell lines. Five cell lines have been observed to produce the desired phytocannabinoid-converting enzyme. Three of these cell lines have shown specific activity for the conversion of the cannabinoid prodrug into an active antineoplastic drug under certain conditions. Efforts to identify the genetic code for the responsible enzyme in these cell lines are underway.
In parallel, an organism has been identified that produces the desired enzyme, and this enzyme has already had its genetic code sequenced. Knowing this sequence, the gene has been successfully synthesized “from scratch” into a vector (carrier vehicle). Work is now underway to transfect (insert) this gene from the vector into the genetic code of a specific human cell line. The cells would then become enzyme-producing “factories” to treat cancer using phytocannabinoids as the prodrug or chemotherapy agent. The cell line is very well suited for encapsulation, and it is the identical parental cell line used by PharmaCyte in its therapy for pancreas cancer. Once complete, testing will commence to analyze the bio-engineered cell line’s ability to catalyze the desired phytocannabinoid-prodrug-activating reaction.
“Learning that the parental cell line used to develop our therapy for pancreas cancer may very well be the same cell line that could be used as the foundation for development of a therapy for different types of cancers using cannabinoids is very good news,” commented PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner. “It is this kind of news that could fast-forward our Cannabis Research Program and allow PharmaCyte to become a serious player in this sector with our ability to develop cannabinoid-based therapies utilizing our proprietary Cell-in-a-Box® live-cell encapsulation technology.”
The second paper, titled “In vitro anti-neoplastic activity of specific phytocannabinoids of Cannabis sativa,” was presented by UNC graduate student Shawn Bydalek. This aspect of the research focuses on the ability of cannabinoids to produce an anti-cancer effect. The in vitro (in the laboratory, but not in animals) effects of select cannabinoids on several human cancer cell lines have been investigated. This work involved treating single-cell layer cultures with increasing levels of CBD and measuring the resultant changes in the cancer cell populations. Results showed that CBD possesses potent dose-related effects against breast, lung, colon and skin cancer cells. Testing of anti-cancer effects against pancreas cancer and glioblastoma (brain cancer) are currently underway.
Waggoner added, “We are quite pleased to present the valuable information that has been generated by Dr. Hyslop and the UNC team as well as showcase the versatility of the Cell-in-a-Box® technology as an advanced therapeutic platform. The pieces of the puzzle are beginning to fall into place.”
For more information on the meeting visit: https://www.acs.org/content/acs/en/meetings/spring-2017.html.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through the encapsulated cells, they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no side effects.
In addition to developing a novel therapy for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a “bio-artificial pancreas” for purposes of insulin production.
Safe Harbor
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
http://finance.yahoo.com/news/pharmacyte-biotech-cannabis-research-program-130000805.html
Keep an eye on VAPE to be the next marijuana stock to run. Low OS (670m) Low Float (444m) Low Market Cap ($2.7 million) Low share price (.0049)
No dilution, bounced off support and it’s on its third leg up and heavy recent volume :)
https://www.barchart.com/stocks/quotes/VAPE/technical-chart?plot=CANDLE&volume=total&data=DO&density=L&pricesOn=1&asPctChange=0&logscale=0&indicators=BBANDS(20,2);SMA(20);SMA(50);PTP(50);CCI(20,100);SMACD(12,26,9);SRSI(14,20);STOSL(14,3);MFI(14,100);PTP(50);ACCUM;SMA(10);SMA(8);SMA(5);BBANDS(20,2);SMA(2)&sym=VAPE&grid=1&height=500&studyheight=200
And don’t forget that this is occurring in one week:
http://www.thecannabist.co/2018/01/12/congress-protect-marijuana-mcclintock-polis/96679/
http://video.foxbusiness.com/v/5709108604001/?#sp=show-clips
https://t.co/GBiNhnIYVd
An exploration mining company turning to cannabis. Reaching outside of the North American continent for a cannabis play.
(Medical Cannabis/Hemp) QBL.AX Queensland Bauxite Ltd.
Fellow Investors, some more info to clearify; the QBL has more then one application of there cannabis products.
Here is another one; https://docs.wixstatic.com/ugd/1943b6_c007317...2f50ca.pdf
The time will tell how they will market them; as equals in the marketplace or different approach to them depending who is the targeted customer.
Some more news; https://www.queenslandbauxite.com/single-post...Production
The other Product; Queensland Bauxite to bring ‘game changing’ medical cannabis pill to market
January 9, 2018
https://smallcaps.com.au/queensland-bauxite-g...ll-market/
Marijuana Stock $GRCU will be releasing a new CBD-based product, which will be hitting shelves within 30 days. https://finance.yahoo.com/news/green-cures-botanical-distribution-inc-110000362.html?soc_src=social-sh&soc_trk=tw
Marijuana Stocks that are and will make you a ton of $$$$$$
$MJNA
$MCOA
$MCIG
$ACBFF
$CBWTF
$IMLFF
$PAOG
$LBTD
$FFRMF
$CBWTF This company will be as large as Auroa, Canopy and Aphria. Buy in below $2.00 while you can, Check our our message board $CBWTF
PERFORMANCE RANKED SINCE 12/22
1. CRONOS GROUP OTCPINK:PRMCF
2. MPX OTCQB:MPXEF
3. EMBLEM OTCPINK:EMMBF
4. ETF NYSE:MJX
5. CANNABIS WHEATON OTCQB:CBWTF
6. AURORA OTCQX:ACBFF
7. NAMASTE OTCQB:NXTTF
8. EMERALD HEALTH OTCQX:EMHTF
9. ISODIAL OTCQB:ISOLF
10.USEI OTCPINK:USEI
11. DOJA OTCPINK:DJACF
12. PHIVIDA OTCPINK:PHVAF
1. PHIVIDA OTCPINK:PHVAF
2. ISODIAL OTCQB:ISOLF
3. DOJA OTCPINK:DJACF
4. CANNABIS WHEATON OTCQB:CBWTF
5. CRONOS GROUP OTCPINK:PRMCF
6. EMBLEM OTCPINK:EMMBF
7. NAMASTE OTCQB:NXTTF
8. EMERALD HEALTH OTCQX:EMHTF
9. MPX OTCQB:MPXEF
10. ETF NYSE:MJX
Top marijuana stocks:
PHOT, GRNH, SIPC, VAPE, VATE
NYSE gets its first weed ETF fund
WEED
A subsidiary of the New York Stock Exchange (NYSE) launches trading on Dec. 26 for its first-ever marijuana fund, the Alternative Agroscience ETF?, marking a major milestone for the burgeoning industry still struggling to obtain access to federally chartered U.S. financial institutions.
As medical and recreational marijuana sales skyrocket in the U.S., the growth is still only in its beginning phases. Twenty-nine states and Washington D.C. have legalized medical marijuana, while eight states and D.C. have legalized recreational sales. (See also: 10 Canadian Marijuana Stocks for Your Portfolio.)
A recent report by Arcview Market Research indicates that the “green rush” should bring in $20.6 billion in revenue by 2020, up from $5.4 billion in 2015. Given the incentive states have to pass marijuana legislation after seeing Colorado rake in $100 million in revenue in its first year and $163 million in its second, a $20 billion-plus estimate could be conservative.
The first-ever U.S.-traded marijuana fund will track the Alternative Agroscience index, an index of companies primarily engaged in the legal cultivation, production and distribution of cannabis, pharmaceutical companies that manufacture or market cannabinoid-related drugs and businesses that make fertilizers and pesticides used in the cultivation of cannabis.
U.S. marijuana companies face difficulty managing their amassed wealth since the federal illegality of weed keeps federally insured banks from doing business with them. Investors, on the other hand, have shown their willingness to get in on the industry’s boom. The Horizon ETF, the first ever marijuana ETF, which launched in Canada in April, has landed $216 million in assets and skyrocketed 44% since its launch.
VAPE
http://vapeholdings.com/
California based marijuana company trading at a half penny per share.
:)
This short list has morphed into a list that is too long ...
PHIVIDA OTCPINK:PHVAF
ISODIAL OTCQB:ISOLF
DOJA OTCPINK:DJACF
CANNABIS WHEATON OTCQB:CBWTF
ORGANIGRAM OTCQB:OGRMF
CRONOS GROUP OTCPINK:PRMCF
EMBLEM OTCPINK:EMMBF
APHRIA OTCQB:APHQF
NAMASTE OTCQB:NXTTF
SUPREME OTCPINK:SPRWF
Premania Phase as per SLEEKSCAPE
UPDATE....
The Twin Peeks “SIPC & VATE”
Both low floaters w/ no toxic notes!,
New update
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137116234
$ACG.C Alliance Growers Closes $833,849 Financing
PHIVIDA OTCPINK:PHVAF
MEDICINE MAN OTCQB:MDCL
DOJA OTCPINK:DJACF
CANNABIS WHEATON OTCQB:CBWTF
DROPPED GOLDEN LEAF. ALTHOUGH I LIKE THE REVENUE, I DO NOT TRUST COMPANY WITH OUTSTANDING SHARE NUMBER AND HISTORY OF REVERSE SPLITS.
Updates On Sir Sleeks Picks !
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137107268
The TWIN PEEKS gonna Be Top If the Pack 2018 !!
$SIPC & $VATE
BOTH LOW FLOATERS & NO TOXIC DEBT IN SITE $$$
Thank you for your patience. I am finally out with my 2018 MJ stock picks.
PHIVIDA CNSX:VIDA
MEDICINE MAN OTCQB:MDCL
DOJA OTCPINK:DJACF
GOLDEN LEAF OTCQB:GLDFF
Top marijuana stocks for 2018:
VAPE GRNH PHOT VATE SIPC
Thank you for your patience. I am finally out with my 2018 MJ stock picks.
PHIVIDA CNSX:VIDA
MEDICINE MAN OTCQB:MDCL
DOJA OTCPINK:DJACF
GOLDEN LEAF OTCQB:GLDFF
PHOT
Heavy accumulation going on right now. :)
Followers
|
101
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1925
|
Created
|
06/05/15
|
Type
|
Free
|
Moderator MarijuanaStocks | |||
Assistants @WolfofWeedST truetrader |
Posts Today
|
0
|
Posts (Total)
|
1925
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |